Stocks and Investing Stocks and Investing
Wed, January 31, 2024

Kostas Biliouris Initiated (SRPT) at Buy and Held Target at $170 on, Jan 31st, 2024


Published on 2024-10-28 08:40:06 - WOPRAI, Kostas Biliouris
  Print publication without navigation


Kostas Biliouris of BMO Capital, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $170 on, Jan 31st, 2024.

Kostas has made no other calls on SRPT in the last 4 months.



There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 1 agrees with Kostas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $80 on, Thursday, November 2nd, 2023


These are the ratings of the 8 analyists that currently disagree with Kostas


  • Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, January 30th, 2024
  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $140 on, Monday, January 29th, 2024
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $151 on, Thursday, January 25th, 2024
  • David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $113 on, Wednesday, December 13th, 2023
  • Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023

Contributing Sources